

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended): A method of promoting functional regeneration of injured nerve fibres in the nervous system comprising administering use of an effective amount of an enteric glial cell, in the manufacture of a medicament for promoting the functional regeneration of injured nerve fibres in the nervous system.
2. (currently amended): The method A use according to claim 1 wherein the enteric glial cells are Type II enteric glial cells.
3. (currently amended): The method A use according to claim 1 or 2 wherein the enteric glial cells are autologous.
4. (currently amended): The method A use according to any one of claims 1 to 3 for use in treating a nerve injury.
5. (currently amended): The method A use according to claim 4 for use in treating a spinal cord injury.
6. (currently amended): The method A use according to any one of claims 1 to 3 for use in treating a neurodegenerative disease.
7. (currently amended): The method A use according to claim 6 wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, Bell's palsy, Pick's disease and amyotrophic lateral sclerosis.
8. (currently amended): The method A use according to any one of claims 1 to 7 wherein the functional regeneration is assessed using a behavioural test.
9. (currently amended): The method A use according to claim 8 wherein the behavioural test is the reflex activation of the cutaneous trunci muscle.

10. (currently amended): A method of inducing the formation of a blood-brain barrier in the nervous system comprising administering use of an effective amount of an enteric glial cell, in the manufacture of a medicament for inducing the formation of a blood-brain barrier in the nervous system.

11. (currently amended): The method A-use according to claim 10 wherein the enteric glial cells are Type II enteric glial cells.

12. (currently amended): The method A-use according to claim 10 or 11 wherein the enteric glial cells are autologous.

13. (currently amended): The method A-use according to any one of claims 10 to 12 for use in treating a nerve injury.

14. (currently amended): The method A-use according to claim 10 for use in treating a spinal cord injury.

15. (currently amended): The method A-use according to any one of claims 10 to 12 for use in treating a neurodegenerative disease.

16. (currently amended): The method A-use according to claim 15 wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, Bell's palsy, Pick's disease and amyotrophic lateral sclerosis.